Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study

Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study

Abstract Midostaurin is used in combination with chemotherapy to treat patients with newly diagnosed FLT3‐mutated acute myeloid leukemia. Chemotherapy‐induced neutropenia exposes these patients to a significant risk of invasive fungal infections (IFIs). International guidelines recommend primary ant...

Full description

Bibliographic Details
Main Authors:	Pierantonio Menna, Francesco Marchesi, Chiara Cattaneo, Anna Candoni, Mario Delia, Gianpaolo Nadali, Alessandra Vatteroni, Crescenza Pasciolla, Salvatore Perrone, Luisa Verga, Daniele Armiento, Maria Ilaria Del Principe, Nicola S. Fracchiolla, Emanuela Salvatorelli, Santina Lupisella, Irene Terrenato, Alessandro Busca, Giorgio Minotti, Livio Pagano
Format:	Article
Language:	English
Published:	Wiley 2023-10-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.13595

Similar Items

P487: MIDOSTAURIN PLASMA EXPOSURE IN PATIENTS WITH FLT3-MUT ACUTE MYELOID LEUKEMIA UNDERGOING POSACONAZOLE PROPHYLAXIS DURING INDUCTION TREATMENT: A PROSPECTIVE MULTICENTRE STUDY FROM THE SEIFEM GROUP
by: Francesco Marchesi, et al.
Published: (2023-08-01)

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study
by: Chiara Cattaneo, et al.
Published: (2022-05-01)

Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients
by: Mehmet Baysal, et al.
Published: (2021-03-01)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
by: Andoni Garitano-Trojaola, et al.
Published: (2021-06-01)

The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report
by: Shujiao He, et al.
Published: (2022-05-01)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
by: Mar Tormo, et al.
Published: (2023-08-01)

P523: MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY IN FLT3 MUTATED AML. “REAL LIFE” DATA VERSUS THE RATIFY STUDY
by: A. De La Fuente, et al.
Published: (2022-06-01)

Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
by: Hao Lu, et al.
Published: (2022-07-01)

MIDOSTAURIN ADDED TO CYTOSINE ARABINOSIDE PLUS IDARUBICIN (“7+3”) IN NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: P Barreto, et al.
Published: (2021-10-01)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
by: Anjali Cremer, et al.
Published: (2023-08-01)

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
by: Karam Ashouri, et al.
Published: (2024-04-01)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
by: Arran Dokal, et al.
Published: (2023-08-01)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
by: Alexander E. Perl, et al.
Published: (2022-05-01)

Posaconazole for lobomycosis
by: Alessandro C. Pasqualotto, et al.
Published: (2021-03-01)

P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON
by: E. N. Oliva, et al.
Published: (2022-06-01)

S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL
by: N. Russell, et al.
Published: (2022-06-01)

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
by: Carolin Joisten, et al.
Published: (2023-08-01)

Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild type acute myeloid leukemia cells
by: Şahin Hande Nur, et al.
Published: (2022-02-01)

Posaconazole‐induced Pseudohyperaldosteronism
by: Jutamart Tantiprawan, et al.
Published: (2021-03-01)

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
by: A. Navickas, et al.
Published: (2022-06-01)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
by: Aneta Szudy-Szczyrek, et al.
Published: (2021-03-01)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
by: Gallogly MM, et al.
Published: (2016-04-01)

P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: J. McCloskey, et al.
Published: (2022-06-01)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
by: Frank G Rücker, et al.
Published: (2023-08-01)

Formation and Characterisation of Posaconazole Hydrate Form
by: Michail Lykouras, et al.
Published: (2022-12-01)

Posaconazole: An Update of Its Clinical Use
by: Simon Leung, et al.
Published: (2015-10-01)

Mineralocorticoid hypertension and hypokalaemia induced by posaconazole
by: Charlotte Boughton, et al.
Published: (2018-02-01)

Posaconazole as rescue therapy in African histoplasmosis
by: Daniel Gonçalves, et al.
Published: (2013-02-01)

Role of posaconazole in the treatment of oropharyngeal candidiasis
by: Voichita Ianas, et al.
Published: (2010-06-01)

Posaconazole as rescue therapy in African histoplasmosis
by: Daniel Gonçalves, et al.
Published: (2013-01-01)

Posaconazole as rescue therapy in African histoplasmosis
by: Daniel Gonçalves, et al.

PB1890: TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN PEDIATRIC PATENTS WITH FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: Dirk Reinhardt, et al.
Published: (2023-08-01)

Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis
by: Ziad Abuhelwa
Published: (2023-05-01)

When Viruses Meet Fungi: Tackling the Enemies in Hematology
by: Alessandro Busca, et al.
Published: (2022-02-01)

A Review of Population Pharmacokinetic Models of Posaconazole
by: Ding Q, et al.
Published: (2022-10-01)

Itraconazole and posaconazole from antifungal to antiviral drugs
by: Falah Hasan Obayes AL-Khikani
Published: (2022-01-01)

Gynecomastia and hypertension in a patient treated with posaconazole
by: George R. Thompson III, et al.
Published: (2020-12-01)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
by: Shengzhuang Tang, et al.
Published: (2021-01-01)

Posaconazole in the management of refractory invasive fungal infections
by: Stefan Langner, et al.
Published: (2008-09-01)

Posaconazole‐induced hypertension in children with cystic fibrosis
by: Rachael Marpole, et al.
Published: (2021-09-01)